

CITATION REPORT

List of articles citing

EU pharmacovigilance regulatory requirements of anticancer biosimilar monoclonal antibodies

DOI: 10.1007/s11096-018-0709-6

International Journal of Clinical Pharmacy, 2018, 40, 778-782.

Source: <https://exaly.com/paper-pdf/71644774/citation-report.pdf>

Version: 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
7	Biotherapeutics: Challenges and Opportunities for Predictive Toxicology of Monoclonal Antibodies. <i>International Journal of Molecular Sciences</i> , 2018 , 19,	6.3	19
6	Overview of this issue: pharmacovigilance, what is new?. <i>International Journal of Clinical Pharmacy</i> , 2018 , 40, 737-739	2.3	6
5	The Breakthrough of Biosimilars: A Twist in the Narrative of Biological Therapy. <i>Biomolecules</i> , 2019 , 9,	5.9	25
4	Monoclonal antibody purification and its progression to commercial scale. <i>Biologicals</i> , 2020 , 63, 1-13	1.8	8
3	Rituximab in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in diffuse large B-cell lymphoma. <i>Therapeutic Advances in Hematology</i> , 2021 , 12, 2040620721989579 ³	5.7	3
2	[Interchangeability of biological products in the Brazilian Unified National Health System (SUS): the main regulatory challenges]. <i>Cadernos De Saude Publica</i> , 2019 , 35, e00053519	3.2	0
1	Therapeutic applications of biosimilar monoclonal antibodies: Systematic review of the efficacy, safety, and immunogenicity in autoimmune disorders. <i>International Immunopharmacology</i> , 2021 , 101, 108305	5.8	